Our results demonstrate that SNHG4 modulates the miR-409-3p/CREB1 axis to exert its function in GC progression, indicating that the SNHG4/miR-409-3p/CREB1 network can be a promising target for GC therapy. This evidence concerns the gene SNHG4 and gastric cancer.